658 related articles for article (PubMed ID: 28388401)
1. PARP Inhibitors for Cancer Therapy.
Lin KY; Kraus WL
Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401
[TBL] [Abstract][Full Text] [Related]
2. Rucaparib Approved for Ovarian Cancer.
Cancer Discov; 2017 Feb; 7(2):120-121. PubMed ID: 28057616
[TBL] [Abstract][Full Text] [Related]
3. Rucaparib: First Global Approval.
Syed YY
Drugs; 2017 Apr; 77(5):585-592. PubMed ID: 28247266
[TBL] [Abstract][Full Text] [Related]
4. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
5. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
6. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
7. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
8. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
9. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
[TBL] [Abstract][Full Text] [Related]
11. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
[TBL] [Abstract][Full Text] [Related]
13. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
15. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ; Westin SN; Coleman RL
Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
[TBL] [Abstract][Full Text] [Related]
16. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
[TBL] [Abstract][Full Text] [Related]
17. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
18. A decade of clinical development of PARP inhibitors in perspective.
Mateo J; Lord CJ; Serra V; Tutt A; Balmaña J; Castroviejo-Bermejo M; Cruz C; Oaknin A; Kaye SB; de Bono JS
Ann Oncol; 2019 Sep; 30(9):1437-1447. PubMed ID: 31218365
[TBL] [Abstract][Full Text] [Related]
19. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
Moore DC; Ringley JT; Patel J
J Pharm Pract; 2019 Apr; 32(2):219-224. PubMed ID: 29166829
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]